Skip to search formSkip to main contentSkip to account menu

C-283

Known as: C 283, C283 
National Institutes of Health

Related topics

Related topics

2 relations
Ledakrin

Broader (1)

Nitracrine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Self-assembled crystalline materials of calcium carbonate and silica
C283 resulting precipitates were characterized by Infrared Spectroscopy, X-ray diffraction and the morphology of crystals was… 
2005
2005
Inclusion compounds from a decomposing host: a cautionary tale
C283 were synthesized and their crystal structures were determined. Unexpectedly all such molecules form interlocked Piedfort… 
1983
1983
1H and 13C NMR characteristics of the anticancerous derivative of acridine: Ledakrin C-283 (nitracrine).
For the anticancerous derivative of acridine--Ledakrin C-283 [1-nitro-9-(3-dimethylaminopropylamino)-acridine . 2HCl-H2O] 1H and… 
1977
1977
Structure of acridines and their effect on RNA synthesis in vitro.
1. Ledakrin (C-283), a 1-nitro-9-aminopropylacridine derivative, inhibits RNA synthesis in vitro if the complex with DNA is… 
1977
1977
The effect of the cytostatic preparation C283 (Ledacrine) on platelet aggregation in human and rabbit plasma in vitro and in vivo.
1976
1976
Antineoplastic activity of C-283 preparation (Ledakrin) in model experiments.
1973
1973
Therapeutic efficacy of compound C-283 in patients with mammary carcinoma.
1973
1973
Biochemical studies of cancer patients treated with acridine derivative (C-283). IV. Changes in the levels of serum haptoglobin and sialic acid.
1972
1972
[Use of C-283 in the treatment of skin cancer].
1971
1971
[Preliminary evaluation of the toxicity of C-283 compound used intravenously].